Safety and Immunogenicity of a Pentavalent Vaccine Compared With Separate Administration of Licensed Equivalent Vaccines in US Infants and Toddlers and Persistence of Antibodies Before a Preschool Booster Dose: A Randomized, Clinical Trial
Our goal was to compare the safety and immunogenicity of a combination vaccine (DTaP(5)-IPV-Hib; Pentacel) with that of its separately administered, US-licensed equivalent vaccines (diphtheria, tetanus, 5-component acellular pertussis vaccine [DTaP(5); Daptacel], inactivated poliovirus vaccine [IPV;...
Gespeichert in:
| Veröffentlicht in: | Pediatrics (Evanston) 2009-01, Vol.123 (1), p.301-312 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 312 |
|---|---|
| container_issue | 1 |
| container_start_page | 301 |
| container_title | Pediatrics (Evanston) |
| container_volume | 123 |
| creator | Guerra, Fernando A Blatter, Mark M Greenberg, David P Pichichero, Michael Noriega, Fernando R on behalf of Pentacel Study Group |
| description | Our goal was to compare the safety and immunogenicity of a combination vaccine (DTaP(5)-IPV-Hib; Pentacel) with that of its separately administered, US-licensed equivalent vaccines (diphtheria, tetanus, 5-component acellular pertussis vaccine [DTaP(5); Daptacel], inactivated poliovirus vaccine [IPV; IPOL], and Haemophilus influenzae type b [Hib] vaccine [ActHIB]), when administered to infants and toddlers concomitantly with other routinely recommended vaccines and to assess antibody persistence from the fourth dose in toddlers to the fifth (preschool) DTaP(5) dose.
In this randomized, multicenter study, 1939 healthy infants were immunized at 2, 4, and 6 months of age with 1 of 3 lots of DTaP(5) coadministered with IPV and Hib vaccines or 1 lot of DTaP(5)-IPV-Hib combination vaccine. Subsequently, 849 of these study participants were given a fourth dose of DTaP(5) and Hib vaccines or a fourth dose of DTaP(5)-IPV-Hib at 1 to 16 months of age. Safety was monitored throughout the study, and blood specimens were obtained to assess antibody responses.
DTaP(5)-IPV-Hib elicited similar or fewer solicited injection-site and systemic reactions as compared with the separate administration of US-licensed DTaP(5), IPV, and Hib vaccines. Seroresponse and seroprotection rates elicited by DTaP(5)-IPV-Hib were noninferior to US-licensed equivalent vaccines after the infant series and after the fourth dose. Children immunized with DTaP(5)-IPV-Hib had higher antibody geometric mean concentrations to pertussis toxoid and filamentous hemagglutinin; children immunized with the separate vaccines had higher responses to pertactin. Hib antibody responses to Hib polysaccharide were nearly identical in the DTaP(5)-IPV-Hib and separate-vaccine groups. Persistence of antibodies to the fifth (preschool) dose was also similar between groups.
DTaP(5)-IPV-Hib combination vaccine was shown to be immunogenic and well tolerated. No clinically important differences in the safety or immunologic profiles were noted for DTaP(5)-IPV-Hib versus the separately administered, US-licensed equivalent vaccines. DTaP(5)-IPV-Hib is a suitable replacement for separately administered DTaP, IPV, and Hib vaccines. |
| doi_str_mv | 10.1542/peds.2007-3317 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_66783440</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A193106483</galeid><sourcerecordid>A193106483</sourcerecordid><originalsourceid>FETCH-LOGICAL-c427t-10b0a1925e17058c5ec3f4115aa595adb45dc03d2f7922508db8448fa6bd66b63</originalsourceid><addsrcrecordid>eNpdkk1vEzEQhlcIREPhyhFZSHBigz_3o7c0FIgUqRVJ4Wh57dnE1a6d2hug_Gn-Al4SUeDkGeuZd16N3ix7TvCUCE7f7sDEKcW4zBkj5YNsQnBd5ZyW4mE2wZiRnGMsTrInMd5gjLko6ePshNSElFVdTLKfK9XCcIeUM2jR93vnN-CstunLt0ihK3CD-qq69KDPSmvrAM19v1MBDPpihy1aQWrUAGhmeutsHFJjvRvHl1aDiwm8uN3bf0Uisg5dr9DCtcoN8ff-tTemg3BorlKRxMBpGKVmbrCNNzYNnkPrA4zeAkS99b5D594nNKB3PsIZmqFPScH39geYN2jeJVdadWgdrOqeZo9a1UV4dnxPs-v3F-v5x3x5-WExny1znW435AQ3WJGaCiAlFpUWoFnLCRFKiVoo03BhNGaGtmVNqcCVaSrOq1YVjSmKpmCn2euD7i742z3EQfY2aug65cDvoyyKsmKc4wS-_A-88fvgkjdJacUELylJUH6ANumI0jrt3QDfB-27DjYgk_P5pZyRmhFc8IolfnrgdfAxBmjlLthehTtJsBxzI8fcyDE3csxNGnhxdLFvejD3-DEoCXh1BFRMx2yDctrGPxxNGKtpeb95azfbbzbAuMmqIVgd_yoJZZJIhgn7Bcgq3oE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>228354721</pqid></control><display><type>article</type><title>Safety and Immunogenicity of a Pentavalent Vaccine Compared With Separate Administration of Licensed Equivalent Vaccines in US Infants and Toddlers and Persistence of Antibodies Before a Preschool Booster Dose: A Randomized, Clinical Trial</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Guerra, Fernando A ; Blatter, Mark M ; Greenberg, David P ; Pichichero, Michael ; Noriega, Fernando R ; on behalf of Pentacel Study Group</creator><creatorcontrib>Guerra, Fernando A ; Blatter, Mark M ; Greenberg, David P ; Pichichero, Michael ; Noriega, Fernando R ; on behalf of Pentacel Study Group ; Pentacel Study Group ; on behalf of the Pentacel Study Group</creatorcontrib><description>Our goal was to compare the safety and immunogenicity of a combination vaccine (DTaP(5)-IPV-Hib; Pentacel) with that of its separately administered, US-licensed equivalent vaccines (diphtheria, tetanus, 5-component acellular pertussis vaccine [DTaP(5); Daptacel], inactivated poliovirus vaccine [IPV; IPOL], and Haemophilus influenzae type b [Hib] vaccine [ActHIB]), when administered to infants and toddlers concomitantly with other routinely recommended vaccines and to assess antibody persistence from the fourth dose in toddlers to the fifth (preschool) DTaP(5) dose.
In this randomized, multicenter study, 1939 healthy infants were immunized at 2, 4, and 6 months of age with 1 of 3 lots of DTaP(5) coadministered with IPV and Hib vaccines or 1 lot of DTaP(5)-IPV-Hib combination vaccine. Subsequently, 849 of these study participants were given a fourth dose of DTaP(5) and Hib vaccines or a fourth dose of DTaP(5)-IPV-Hib at 1 to 16 months of age. Safety was monitored throughout the study, and blood specimens were obtained to assess antibody responses.
DTaP(5)-IPV-Hib elicited similar or fewer solicited injection-site and systemic reactions as compared with the separate administration of US-licensed DTaP(5), IPV, and Hib vaccines. Seroresponse and seroprotection rates elicited by DTaP(5)-IPV-Hib were noninferior to US-licensed equivalent vaccines after the infant series and after the fourth dose. Children immunized with DTaP(5)-IPV-Hib had higher antibody geometric mean concentrations to pertussis toxoid and filamentous hemagglutinin; children immunized with the separate vaccines had higher responses to pertactin. Hib antibody responses to Hib polysaccharide were nearly identical in the DTaP(5)-IPV-Hib and separate-vaccine groups. Persistence of antibodies to the fifth (preschool) dose was also similar between groups.
DTaP(5)-IPV-Hib combination vaccine was shown to be immunogenic and well tolerated. No clinically important differences in the safety or immunologic profiles were noted for DTaP(5)-IPV-Hib versus the separately administered, US-licensed equivalent vaccines. DTaP(5)-IPV-Hib is a suitable replacement for separately administered DTaP, IPV, and Hib vaccines.</description><identifier>ISSN: 0031-4005</identifier><identifier>EISSN: 1098-4275</identifier><identifier>DOI: 10.1542/peds.2007-3317</identifier><identifier>PMID: 19117896</identifier><identifier>CODEN: PEDIAU</identifier><language>eng</language><publisher>Elk Grove Village, IL: Am Acad Pediatrics</publisher><subject>Antibodies ; Antibodies, Bacterial - biosynthesis ; Antibodies, Bacterial - blood ; Antibodies, Viral - biosynthesis ; Antibodies, Viral - blood ; Bacterial diseases ; Bacterial diseases of the nervous system. Bacterial myositis ; Bacterial Vaccines - administration & dosage ; Bacterial Vaccines - adverse effects ; Bacterial Vaccines - pharmacokinetics ; Biological and medical sciences ; Child ; Child, Preschool ; Clinical trials ; Comparative analysis ; Demographic aspects ; Diphtheria-Tetanus-acellular Pertussis Vaccines - administration & dosage ; Diphtheria-Tetanus-acellular Pertussis Vaccines - adverse effects ; Diphtheria-Tetanus-acellular Pertussis Vaccines - pharmacokinetics ; Diphtheria-Tetanus-Pertussis Vaccine ; Dosage and administration ; Ent and stomatologic bacterial diseases ; Female ; General aspects ; Haemophilus Vaccines ; Hib vaccines ; Human bacterial diseases ; Humans ; Immunization Schedule ; Immunization, Secondary - adverse effects ; Immunization, Secondary - methods ; Infant ; Infectious diseases ; Male ; Medical sciences ; Pediatrics ; Pertussis vaccines ; Physiological aspects ; Poliovirus Vaccine, Inactivated - administration & dosage ; Poliovirus Vaccine, Inactivated - adverse effects ; Poliovirus Vaccine, Inactivated - pharmacokinetics ; Safety ; Therapeutic Equivalency ; United States ; Vaccines ; Vaccines, Combined - administration & dosage ; Vaccines, Combined - adverse effects ; Vaccines, Combined - pharmacokinetics ; Vaccines, Conjugate - administration & dosage ; Vaccines, Conjugate - adverse effects ; Vaccines, Conjugate - metabolism ; Viral antibodies</subject><ispartof>Pediatrics (Evanston), 2009-01, Vol.123 (1), p.301-312</ispartof><rights>2009 INIST-CNRS</rights><rights>Copyright American Academy of Pediatrics Jan 2009</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c427t-10b0a1925e17058c5ec3f4115aa595adb45dc03d2f7922508db8448fa6bd66b63</citedby><cites>FETCH-LOGICAL-c427t-10b0a1925e17058c5ec3f4115aa595adb45dc03d2f7922508db8448fa6bd66b63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21173927$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19117896$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Guerra, Fernando A</creatorcontrib><creatorcontrib>Blatter, Mark M</creatorcontrib><creatorcontrib>Greenberg, David P</creatorcontrib><creatorcontrib>Pichichero, Michael</creatorcontrib><creatorcontrib>Noriega, Fernando R</creatorcontrib><creatorcontrib>on behalf of Pentacel Study Group</creatorcontrib><creatorcontrib>Pentacel Study Group</creatorcontrib><creatorcontrib>on behalf of the Pentacel Study Group</creatorcontrib><title>Safety and Immunogenicity of a Pentavalent Vaccine Compared With Separate Administration of Licensed Equivalent Vaccines in US Infants and Toddlers and Persistence of Antibodies Before a Preschool Booster Dose: A Randomized, Clinical Trial</title><title>Pediatrics (Evanston)</title><addtitle>Pediatrics</addtitle><description>Our goal was to compare the safety and immunogenicity of a combination vaccine (DTaP(5)-IPV-Hib; Pentacel) with that of its separately administered, US-licensed equivalent vaccines (diphtheria, tetanus, 5-component acellular pertussis vaccine [DTaP(5); Daptacel], inactivated poliovirus vaccine [IPV; IPOL], and Haemophilus influenzae type b [Hib] vaccine [ActHIB]), when administered to infants and toddlers concomitantly with other routinely recommended vaccines and to assess antibody persistence from the fourth dose in toddlers to the fifth (preschool) DTaP(5) dose.
In this randomized, multicenter study, 1939 healthy infants were immunized at 2, 4, and 6 months of age with 1 of 3 lots of DTaP(5) coadministered with IPV and Hib vaccines or 1 lot of DTaP(5)-IPV-Hib combination vaccine. Subsequently, 849 of these study participants were given a fourth dose of DTaP(5) and Hib vaccines or a fourth dose of DTaP(5)-IPV-Hib at 1 to 16 months of age. Safety was monitored throughout the study, and blood specimens were obtained to assess antibody responses.
DTaP(5)-IPV-Hib elicited similar or fewer solicited injection-site and systemic reactions as compared with the separate administration of US-licensed DTaP(5), IPV, and Hib vaccines. Seroresponse and seroprotection rates elicited by DTaP(5)-IPV-Hib were noninferior to US-licensed equivalent vaccines after the infant series and after the fourth dose. Children immunized with DTaP(5)-IPV-Hib had higher antibody geometric mean concentrations to pertussis toxoid and filamentous hemagglutinin; children immunized with the separate vaccines had higher responses to pertactin. Hib antibody responses to Hib polysaccharide were nearly identical in the DTaP(5)-IPV-Hib and separate-vaccine groups. Persistence of antibodies to the fifth (preschool) dose was also similar between groups.
DTaP(5)-IPV-Hib combination vaccine was shown to be immunogenic and well tolerated. No clinically important differences in the safety or immunologic profiles were noted for DTaP(5)-IPV-Hib versus the separately administered, US-licensed equivalent vaccines. DTaP(5)-IPV-Hib is a suitable replacement for separately administered DTaP, IPV, and Hib vaccines.</description><subject>Antibodies</subject><subject>Antibodies, Bacterial - biosynthesis</subject><subject>Antibodies, Bacterial - blood</subject><subject>Antibodies, Viral - biosynthesis</subject><subject>Antibodies, Viral - blood</subject><subject>Bacterial diseases</subject><subject>Bacterial diseases of the nervous system. Bacterial myositis</subject><subject>Bacterial Vaccines - administration & dosage</subject><subject>Bacterial Vaccines - adverse effects</subject><subject>Bacterial Vaccines - pharmacokinetics</subject><subject>Biological and medical sciences</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Clinical trials</subject><subject>Comparative analysis</subject><subject>Demographic aspects</subject><subject>Diphtheria-Tetanus-acellular Pertussis Vaccines - administration & dosage</subject><subject>Diphtheria-Tetanus-acellular Pertussis Vaccines - adverse effects</subject><subject>Diphtheria-Tetanus-acellular Pertussis Vaccines - pharmacokinetics</subject><subject>Diphtheria-Tetanus-Pertussis Vaccine</subject><subject>Dosage and administration</subject><subject>Ent and stomatologic bacterial diseases</subject><subject>Female</subject><subject>General aspects</subject><subject>Haemophilus Vaccines</subject><subject>Hib vaccines</subject><subject>Human bacterial diseases</subject><subject>Humans</subject><subject>Immunization Schedule</subject><subject>Immunization, Secondary - adverse effects</subject><subject>Immunization, Secondary - methods</subject><subject>Infant</subject><subject>Infectious diseases</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Pediatrics</subject><subject>Pertussis vaccines</subject><subject>Physiological aspects</subject><subject>Poliovirus Vaccine, Inactivated - administration & dosage</subject><subject>Poliovirus Vaccine, Inactivated - adverse effects</subject><subject>Poliovirus Vaccine, Inactivated - pharmacokinetics</subject><subject>Safety</subject><subject>Therapeutic Equivalency</subject><subject>United States</subject><subject>Vaccines</subject><subject>Vaccines, Combined - administration & dosage</subject><subject>Vaccines, Combined - adverse effects</subject><subject>Vaccines, Combined - pharmacokinetics</subject><subject>Vaccines, Conjugate - administration & dosage</subject><subject>Vaccines, Conjugate - adverse effects</subject><subject>Vaccines, Conjugate - metabolism</subject><subject>Viral antibodies</subject><issn>0031-4005</issn><issn>1098-4275</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkk1vEzEQhlcIREPhyhFZSHBigz_3o7c0FIgUqRVJ4Wh57dnE1a6d2hug_Gn-Al4SUeDkGeuZd16N3ix7TvCUCE7f7sDEKcW4zBkj5YNsQnBd5ZyW4mE2wZiRnGMsTrInMd5gjLko6ePshNSElFVdTLKfK9XCcIeUM2jR93vnN-CstunLt0ihK3CD-qq69KDPSmvrAM19v1MBDPpihy1aQWrUAGhmeutsHFJjvRvHl1aDiwm8uN3bf0Uisg5dr9DCtcoN8ff-tTemg3BorlKRxMBpGKVmbrCNNzYNnkPrA4zeAkS99b5D594nNKB3PsIZmqFPScH39geYN2jeJVdadWgdrOqeZo9a1UV4dnxPs-v3F-v5x3x5-WExny1znW435AQ3WJGaCiAlFpUWoFnLCRFKiVoo03BhNGaGtmVNqcCVaSrOq1YVjSmKpmCn2euD7i742z3EQfY2aug65cDvoyyKsmKc4wS-_A-88fvgkjdJacUELylJUH6ANumI0jrt3QDfB-27DjYgk_P5pZyRmhFc8IolfnrgdfAxBmjlLthehTtJsBxzI8fcyDE3csxNGnhxdLFvejD3-DEoCXh1BFRMx2yDctrGPxxNGKtpeb95azfbbzbAuMmqIVgd_yoJZZJIhgn7Bcgq3oE</recordid><startdate>20090101</startdate><enddate>20090101</enddate><creator>Guerra, Fernando A</creator><creator>Blatter, Mark M</creator><creator>Greenberg, David P</creator><creator>Pichichero, Michael</creator><creator>Noriega, Fernando R</creator><creator>on behalf of Pentacel Study Group</creator><general>Am Acad Pediatrics</general><general>American Academy of Pediatrics</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TS</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>U9A</scope><scope>7X8</scope></search><sort><creationdate>20090101</creationdate><title>Safety and Immunogenicity of a Pentavalent Vaccine Compared With Separate Administration of Licensed Equivalent Vaccines in US Infants and Toddlers and Persistence of Antibodies Before a Preschool Booster Dose: A Randomized, Clinical Trial</title><author>Guerra, Fernando A ; Blatter, Mark M ; Greenberg, David P ; Pichichero, Michael ; Noriega, Fernando R ; on behalf of Pentacel Study Group</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c427t-10b0a1925e17058c5ec3f4115aa595adb45dc03d2f7922508db8448fa6bd66b63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Antibodies</topic><topic>Antibodies, Bacterial - biosynthesis</topic><topic>Antibodies, Bacterial - blood</topic><topic>Antibodies, Viral - biosynthesis</topic><topic>Antibodies, Viral - blood</topic><topic>Bacterial diseases</topic><topic>Bacterial diseases of the nervous system. Bacterial myositis</topic><topic>Bacterial Vaccines - administration & dosage</topic><topic>Bacterial Vaccines - adverse effects</topic><topic>Bacterial Vaccines - pharmacokinetics</topic><topic>Biological and medical sciences</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Clinical trials</topic><topic>Comparative analysis</topic><topic>Demographic aspects</topic><topic>Diphtheria-Tetanus-acellular Pertussis Vaccines - administration & dosage</topic><topic>Diphtheria-Tetanus-acellular Pertussis Vaccines - adverse effects</topic><topic>Diphtheria-Tetanus-acellular Pertussis Vaccines - pharmacokinetics</topic><topic>Diphtheria-Tetanus-Pertussis Vaccine</topic><topic>Dosage and administration</topic><topic>Ent and stomatologic bacterial diseases</topic><topic>Female</topic><topic>General aspects</topic><topic>Haemophilus Vaccines</topic><topic>Hib vaccines</topic><topic>Human bacterial diseases</topic><topic>Humans</topic><topic>Immunization Schedule</topic><topic>Immunization, Secondary - adverse effects</topic><topic>Immunization, Secondary - methods</topic><topic>Infant</topic><topic>Infectious diseases</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Pediatrics</topic><topic>Pertussis vaccines</topic><topic>Physiological aspects</topic><topic>Poliovirus Vaccine, Inactivated - administration & dosage</topic><topic>Poliovirus Vaccine, Inactivated - adverse effects</topic><topic>Poliovirus Vaccine, Inactivated - pharmacokinetics</topic><topic>Safety</topic><topic>Therapeutic Equivalency</topic><topic>United States</topic><topic>Vaccines</topic><topic>Vaccines, Combined - administration & dosage</topic><topic>Vaccines, Combined - adverse effects</topic><topic>Vaccines, Combined - pharmacokinetics</topic><topic>Vaccines, Conjugate - administration & dosage</topic><topic>Vaccines, Conjugate - adverse effects</topic><topic>Vaccines, Conjugate - metabolism</topic><topic>Viral antibodies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Guerra, Fernando A</creatorcontrib><creatorcontrib>Blatter, Mark M</creatorcontrib><creatorcontrib>Greenberg, David P</creatorcontrib><creatorcontrib>Pichichero, Michael</creatorcontrib><creatorcontrib>Noriega, Fernando R</creatorcontrib><creatorcontrib>on behalf of Pentacel Study Group</creatorcontrib><creatorcontrib>Pentacel Study Group</creatorcontrib><creatorcontrib>on behalf of the Pentacel Study Group</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Physical Education Index</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Pediatrics (Evanston)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Guerra, Fernando A</au><au>Blatter, Mark M</au><au>Greenberg, David P</au><au>Pichichero, Michael</au><au>Noriega, Fernando R</au><au>on behalf of Pentacel Study Group</au><aucorp>Pentacel Study Group</aucorp><aucorp>on behalf of the Pentacel Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety and Immunogenicity of a Pentavalent Vaccine Compared With Separate Administration of Licensed Equivalent Vaccines in US Infants and Toddlers and Persistence of Antibodies Before a Preschool Booster Dose: A Randomized, Clinical Trial</atitle><jtitle>Pediatrics (Evanston)</jtitle><addtitle>Pediatrics</addtitle><date>2009-01-01</date><risdate>2009</risdate><volume>123</volume><issue>1</issue><spage>301</spage><epage>312</epage><pages>301-312</pages><issn>0031-4005</issn><eissn>1098-4275</eissn><coden>PEDIAU</coden><abstract>Our goal was to compare the safety and immunogenicity of a combination vaccine (DTaP(5)-IPV-Hib; Pentacel) with that of its separately administered, US-licensed equivalent vaccines (diphtheria, tetanus, 5-component acellular pertussis vaccine [DTaP(5); Daptacel], inactivated poliovirus vaccine [IPV; IPOL], and Haemophilus influenzae type b [Hib] vaccine [ActHIB]), when administered to infants and toddlers concomitantly with other routinely recommended vaccines and to assess antibody persistence from the fourth dose in toddlers to the fifth (preschool) DTaP(5) dose.
In this randomized, multicenter study, 1939 healthy infants were immunized at 2, 4, and 6 months of age with 1 of 3 lots of DTaP(5) coadministered with IPV and Hib vaccines or 1 lot of DTaP(5)-IPV-Hib combination vaccine. Subsequently, 849 of these study participants were given a fourth dose of DTaP(5) and Hib vaccines or a fourth dose of DTaP(5)-IPV-Hib at 1 to 16 months of age. Safety was monitored throughout the study, and blood specimens were obtained to assess antibody responses.
DTaP(5)-IPV-Hib elicited similar or fewer solicited injection-site and systemic reactions as compared with the separate administration of US-licensed DTaP(5), IPV, and Hib vaccines. Seroresponse and seroprotection rates elicited by DTaP(5)-IPV-Hib were noninferior to US-licensed equivalent vaccines after the infant series and after the fourth dose. Children immunized with DTaP(5)-IPV-Hib had higher antibody geometric mean concentrations to pertussis toxoid and filamentous hemagglutinin; children immunized with the separate vaccines had higher responses to pertactin. Hib antibody responses to Hib polysaccharide were nearly identical in the DTaP(5)-IPV-Hib and separate-vaccine groups. Persistence of antibodies to the fifth (preschool) dose was also similar between groups.
DTaP(5)-IPV-Hib combination vaccine was shown to be immunogenic and well tolerated. No clinically important differences in the safety or immunologic profiles were noted for DTaP(5)-IPV-Hib versus the separately administered, US-licensed equivalent vaccines. DTaP(5)-IPV-Hib is a suitable replacement for separately administered DTaP, IPV, and Hib vaccines.</abstract><cop>Elk Grove Village, IL</cop><pub>Am Acad Pediatrics</pub><pmid>19117896</pmid><doi>10.1542/peds.2007-3317</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0031-4005 |
| ispartof | Pediatrics (Evanston), 2009-01, Vol.123 (1), p.301-312 |
| issn | 0031-4005 1098-4275 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_66783440 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Antibodies Antibodies, Bacterial - biosynthesis Antibodies, Bacterial - blood Antibodies, Viral - biosynthesis Antibodies, Viral - blood Bacterial diseases Bacterial diseases of the nervous system. Bacterial myositis Bacterial Vaccines - administration & dosage Bacterial Vaccines - adverse effects Bacterial Vaccines - pharmacokinetics Biological and medical sciences Child Child, Preschool Clinical trials Comparative analysis Demographic aspects Diphtheria-Tetanus-acellular Pertussis Vaccines - administration & dosage Diphtheria-Tetanus-acellular Pertussis Vaccines - adverse effects Diphtheria-Tetanus-acellular Pertussis Vaccines - pharmacokinetics Diphtheria-Tetanus-Pertussis Vaccine Dosage and administration Ent and stomatologic bacterial diseases Female General aspects Haemophilus Vaccines Hib vaccines Human bacterial diseases Humans Immunization Schedule Immunization, Secondary - adverse effects Immunization, Secondary - methods Infant Infectious diseases Male Medical sciences Pediatrics Pertussis vaccines Physiological aspects Poliovirus Vaccine, Inactivated - administration & dosage Poliovirus Vaccine, Inactivated - adverse effects Poliovirus Vaccine, Inactivated - pharmacokinetics Safety Therapeutic Equivalency United States Vaccines Vaccines, Combined - administration & dosage Vaccines, Combined - adverse effects Vaccines, Combined - pharmacokinetics Vaccines, Conjugate - administration & dosage Vaccines, Conjugate - adverse effects Vaccines, Conjugate - metabolism Viral antibodies |
| title | Safety and Immunogenicity of a Pentavalent Vaccine Compared With Separate Administration of Licensed Equivalent Vaccines in US Infants and Toddlers and Persistence of Antibodies Before a Preschool Booster Dose: A Randomized, Clinical Trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T18%3A45%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20and%20Immunogenicity%20of%20a%20Pentavalent%20Vaccine%20Compared%20With%20Separate%20Administration%20of%20Licensed%20Equivalent%20Vaccines%20in%20US%20Infants%20and%20Toddlers%20and%20Persistence%20of%20Antibodies%20Before%20a%20Preschool%20Booster%20Dose:%20A%20Randomized,%20Clinical%20Trial&rft.jtitle=Pediatrics%20(Evanston)&rft.au=Guerra,%20Fernando%20A&rft.aucorp=Pentacel%20Study%20Group&rft.date=2009-01-01&rft.volume=123&rft.issue=1&rft.spage=301&rft.epage=312&rft.pages=301-312&rft.issn=0031-4005&rft.eissn=1098-4275&rft.coden=PEDIAU&rft_id=info:doi/10.1542/peds.2007-3317&rft_dat=%3Cgale_proqu%3EA193106483%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=228354721&rft_id=info:pmid/19117896&rft_galeid=A193106483&rfr_iscdi=true |